Chul Kim

发表

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing

B. Halmos, S. Dacic, P. Ma, 2022, JTO clinical and research reports.

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report

Stephen V. Liu, J. Reuss, Greg Jones, 2022, JTO clinical and research reports.

Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.

E. Yi, Kyung-Hee Kim, K. Suh, 2012, Histology and histopathology.

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

S. Groshen, C. Paweletz, H. Wakelee, 2022, Journal of Clinical Oncology.

Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis.

B. Halmos, P. Sackstein, Stephen V. Liu, 2022, JCO precision oncology.

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset

M. Socinski, S. Ou, B. Halmos, 2023, Translational oncology.

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

M. Socinski, J. Nieva, A. Wozniak, 2023, Frontiers in oncology.

High levels of expression of Trop-2 in thymic epithelial tumors.

B. Kallakury, Jaeil Ahn, Stephen V. Liu, 2023, Lung cancer.

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer.

B. Halmos, H. Borghaei, H. Mamdani, 2024, JCO precision oncology.

Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.

E. Yi, Kyung-Hee Kim, K. Suh, 2012, Histology and histopathology.